Clinical trials
MRD clinical trials
Below are recruiting mrd clinical trials, each written for real people, not researchers. We’re tracking 110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05965024Recruiting
Using ctDNA blood tests to predict lung cancer return after surgery
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06005818RecruitingPhase 2
MRD-guided therapy for kidney cancer after surgery
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Birmingham, AlabamaAges 18 years+ - NCT06066905Recruiting
Study of chidamide and azacitidine for AML patients with MRD after transplant
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Guangzhou, GuangdongAges 18 years+ - NCT06109233Recruiting
MRD-guided treatment for newly diagnosed myeloma
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
Changchun, JilinAges 18 years+ - NCT06144606RecruitingPhase 2
KTE-X19 CAR T for MRD+ B-ALL
This trial tests a CAR T-cell therapy called KTE-X19 for people with B-cell ALL that is in remission but still has trace disease (MRD-positive). The goal is to see if this treatment can eliminate the remaining cancer cells and prevent relapse.
Tampa, FloridaAges 18 years+ - NCT06182917Recruiting
MRD detection for ovarian cancer with low CA125
This study looks at whether a blood test (MRD) can predict how well treatment works for ovarian cancer patients who do not have high CA125 levels, helping doctors choose better therapies.
Chengdu, SichuanAges Any age - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT06204484Recruiting
MRD-guided Chemo Timing for Early Colon Cancer
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
Guangzhou, GuangdongAges 18–70 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06230185Recruiting
Blood test to monitor treatment response in triple-negative breast cancer
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
Tucson, ArizonaAges 18 years+ - NCT06237192Recruiting
Treatment for adults with Ph-negative ALL
This trial tests a less intensive but continuous treatment approach for adults newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to improve outcomes by using minimal residual disease (MRD) to guide therapy.
MoscowAges 18–55 - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT06287814Recruiting
Blood test to detect leftover cancer DNA in colorectal cancer patients
This study uses a simple blood test (liquid biopsy) to look for tiny bits of tumor DNA remaining after colorectal cancer surgery. It aims to see if the test can help predict whether the cancer will come back, especially in people with stage III cancer who will receive chemotherapy.
Montpellier, HéraultAges 18 years+ - NCT06287723Recruiting
Blood test for cancer DNA after liver surgery in colorectal cancer
This study uses a simple blood test (liquid biopsy) to look for tiny bits of cancer DNA after surgery for colorectal cancer that spread to the liver. It aims to see if this test can find cancer earlier than standard scans, which may help guide future treatment decisions.
MontpellierAges 18 years+ - NCT06287749Recruiting
Liquid biopsy for monitoring pancreatic cancer after surgery
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
Montpellier, HéraultAges 18 years+ - NCT06301425Recruiting
Transplant study for high-risk AML based on MRD response
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
BeijingAges 16–65 - NCT06341907RecruitingPhase 2/Phase 3
Vaccine and blood test to prevent ovarian cancer return
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
Wenzhou, ZhejiangAges 18–70 - NCT06358222Recruiting
Lung cancer trial testing blood test and PET scan for spread
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
ShanghaiAges 18–75 - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+ - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06426511RecruitingPhase 2
Testing toripalimab after lung cancer surgery using ctDNA
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
Guangzhou, GuangdongAges 18–75 - NCT06463717Recruiting
Stem cell transplant timing for multiple myeloma with no cancer cells left
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hangzhou, ZhejiangAges 18–70 - NCT06479460Recruiting
Blood test monitoring during chemo before surgery for HER2-positive breast cancer
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Nanjing, JiangsuAges 18–75 - NCT06498752RecruitingPhase 2
MRD-guided consolidation therapy after radiation for esophageal cancer
This trial looks at whether a treatment guided by a blood test (MRD) after radiation can help prevent esophageal cancer from coming back. It tests a personalized approach to decide if more treatment is needed.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mrd?
- Yes. Clin2 currently lists 110 recruiting mrd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mrd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mrd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.